- Article
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
- Amélie Huynh Le Maux,
- Bernadette Pignol,
- Delphine Behr-Roussel,
- Jean-Luc Blachon,
- Pierre-Etienne Chabrier,
- Sandrine Compagnie,
- Philippe Picaut,
- Jacques Bernabé,
- François Giuliano and
- Pierre Denys
Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protoc...

